Table of Contents
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 20, 2008
VAXGEN, INC.
(Exact name of Registrant as Specified in its Charter)
DELAWARE (State or other jurisdiction of organization) | 0-26483 (Commission File Number) | 94-3236309 (I.R.S. Employer incorporation or Identification Number) |
349 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CALIFORNIA 94080
(Address of Principal Administrative Offices)
Registrant’s Telephone Number, Including Area Code: (650) 624-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
þ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 8.01. Other Events | ||||||||
Item 9.01 Financial Statements and Exhibits | ||||||||
SIGNATURE | ||||||||
EXHIBIT INDEX | ||||||||
EXHIBIT 99.1 |
Table of Contents
SECTION 1—REGISTRANT’S BUSINESS AND OPERATIONS
Item 8.01. | Other Events |
On March 20, 2008 VaxGen issued an open letter in the form of a press release to its stockholders titled “VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger with Raven.”
This press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.
Item 9.01 | Financial Statements and Exhibits |
Exhibit No. | Description | |
99.1 | Press release dated March 20, 2008 titled “VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger with Raven” |
Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VaxGen, Inc. (Registrant) | ||||
Dated: March 20, 2008 | By: | /s/ Matthew J. Pfeffer | ||
Matthew J. Pfeffer | ||||
Senior Vice President, Finance and Administration and Chief Financial Officer | ||||